Joint Patent Application Filed for lncRNA-Targeting Drugs
Filed with TSE · · 3 pages · English
Veritas In Silico Inc. (hereinafter referred to as “the Company”) is pleased to announce progress in its Joint Research on nucleic acid drugs (antisense oligonucleotides: ASOs*1) with Mitsubishi Gas Chemical Company, Inc. (hereinafter referred to as “MGC”, “the Joint Research”). The Joint Research was previously highlighted in the announcement dated July 3, 2025, titled “Mitsubishi Gas Chemical an
In the deck
Earlier from Veritas In Silico
- Personnel Changes in Executive Officer
- TABLE-Veritas In Silico -2025 parent results
- TABLE-Veritas In Silico - 9-MTH parent results
- TABLE-Veritas In Silico -2025 parent forecast
Later from Veritas In Silico
- Non-consolidated Financial Results for the Six Months Ended June 30, 2026 [Under Japanese GAAP]
- Notice Concerning Achievement of Research Milestone under Joint Drug Discovery with Toray Industries, Inc.
- Notice of Completion of Payment for #5 and #6 to #9 Share Acquisition Rights by Third-Party Allotment
- Syntara and Veritas In Silico sign MoU to Accelerate Joint Discovery Research for mRNA-Targeted Compounds
- Monthly Status of Exercise of #5 (with Exercise Price Adjustment Clause) and #6 to #9 Share Acquisition Rights(with Target Issue and Adjustment Optio
Follow Veritas In Silico into a list and get an email when it puts out news.
Follow Veritas In Silico